Modulation of the metabotropic glutamate type 2 (mGlu2) receptor is considered a promising target for the treatment of central nervous system diseases such as schizophrenia. Here, we describe the pharmacological properties of the novel mGlu2 receptor positive allosteric modulator (PAM) 3-cyano-1-cyclopropylmethyl-4-(4-phenyl-piperidin-1-yl)-pyridine-2(1H)-one (JNJ-40068782) and its radioligand 
Introduction
Glutamate is the major excitatory neurotransmitter in the central nervous system of vertebrates and elicits and modulates synaptic responses by activating ionotropic or metabotropic glutamate (mGlu) receptors (Kew and Kemp, 2005) . To date, dx.doi.org/10.1124/jpet.113.204990. s This article has supplemental material available at jpet.aspetjournals.org.
ABBREVIATIONS: 5HT 2A , 5-hydroxytryptamine 2A ; BINA, biphenyl-indanone A; BSA, bovine serum albumin; CCK, cholecystokinin; CHO, Chinese hamster ovary; CI, confidence interval; DCG-IV, (2S,29R,39R)-2-(29,39-dicarboxylcyclopropyl)glycine; EEG, electroencephalogram; [ eight mGlu receptor subtypes have been cloned and classified into three groups based on sequence homology, pharmacological profile, and preferential signal transduction pathway (Niswender and Conn, 2010) .
The drug discovery efforts related to group III mGlu receptors have lagged behind (Lavreysen and Dautzenberg, 2008) , and various research groups have focused on the development of ligands acting at group I and II receptors. For example, mGlu1 receptor blockade is thought to have anxiolyticlike properties and to relieve pain (Tatarczynska et al., 2001 ; Varney and Gereau, 2002; Steckler et al., 2005) , whereas inhibitors of the mGlu5 receptor are believed to be alternative treatments for anxiety, depression, and Fragile X and mGlu5 activators may have beneficial effects in schizophrenia (Spooren et al., 2003; Auerbach et al., 2011) . Because group II mGlu receptors reduce transmission at glutamatergic synapses in brain regions where excessive glutamatergic transmission may be implicated in the pathophysiology of anxiety and schizophrenia, it is hypothesized that activation of group II mGlu receptors may provide anxiolytic and/or antipsychotic effects (Swanson et al., 2005) .
Accordingly, mGlu2/3 receptor agonists, such as (2)-(1R,4S, 5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039), are effective in a number of animal models of schizophrenia (Rorick-Kehn et al., 2007) and anxiety (Helton et al., 1998; Tizzano et al., 2002; Swanson et al., 2005; Witkin et al., 2007) . These observations have been extended into the clinic where (1R,4S,5S,6S)-2-thiabicyclo[3. 1.0]hexane-4,6-dicarboxylic acid, 4-[(2S)-2-amino-4(methylthio)-1-oxobutyl]amino-, 2,2-dioxide monohydrate (LY2140023), a methionine amide prodrug of LY404039, has been shown to demonstrate efficacy in a phase 2 study in schizophrenia patients (Patil et al., 2007; Mezler et al., 2010) , although these observations could not be confirmed in a follow-up trial (Kinon et al., 2011) . The structurally related analog (1S,2S,5R,6S)-(1)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740) was able to reduce anxiety in healthy volunteers in a fearpotentiated startle model (Grillon et al., 2003) and attenuated CO 2 -induced panic in subjects with panic disorder . These anxiolytic-like properties were reproduced in patients with generalized anxiety disorder using LY354740 (Michelson et al., 2005) as well as its prodrug (1S,2S,5R,6S)-2[(29S)-(29-amino)-propionyl]amino-bicyclo [3.1.0] hexane-2,6-dicar boxylic acid hydrochloride (LY544344) (Dunayevich et al., 2008) .
The use of knockout mice lacking either mGlu2 or mGlu3 receptors has further refined our understanding of the mechanism of action of mGlu2/3 receptor agonists. For example, the anxiolytic actions of LY354740 in the elevated plus maze test require the expression of one or both of these receptors . On the other hand, mGlu2 rather than mGlu3 receptors appear to be responsible for the antipsychotic-like properties of LY404039 (Fell et al., 2008) , (2)-2-oxa-4-aminobicyclo [3.1.0] hexane-4,6-dicarboxylic acid (LY379268) (Woolley et al., 2008) , and LY314582, which is the racemate of LY354740 (Spooren et al., 2000) . On the basis of the collective data using mGlu2/3-selective agonists as well as mice lacking either the mGlu2 or mGlu3 receptor, the mGlu2 receptor would appear to be an attractive potential therapeutic target (Niswender and Conn, 2010) . mGlu2-positive allosteric modulators (PAMs) that bind at a receptor site that is different (i.e., allosteric) from glutamate offer an alternative approach for enhancing mGlu2 activity.
mGlu2 PAMs have minimal effects on their own but increase the response of glutamate. As a consequence, mGlu2 receptor PAMs offer an opportunity to enhance mGlu2 receptor signaling by maintaining activity based on transient release of glutamate but have a lower risk of tolerance development (Conn et al., 2008 (Conn et al., , 2009 ). 2,2,2-Trifluoro-N-[4-(2-methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide (LY487379) was identified as the first mGlu2 receptor-specific PAM (Johnson et al., 2003) and was active in animal models predictive of anxiolytic or antipsychotic activity (Johnson et al., 2003 Galici et al., 2005) , providing preclinical proof of concept that PAMs can mimic aspects of the pharmacology of agonists. Minimal efficacy at sufficiently low doses as well as short duration of action, however, limited its use for further development. Pinkerton et al. (2005) reported an alternative series of mGlu2 PAMs, of which the prototypic example biphenyl-indanone A (BINA) demonstrates long-lasting activity in some animal models used to predict potential antipsychotic and anxiolytic activity (Galici et al., 2006) . Recently, the structurally novel allosteric potentiator N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenxoy)methylbenzyl)-1-methyl-1H-imidazo-4-carboxamide (THIIC; also known as LY2607540), which seems to have activity in models predicting either anxiolytic or antidepressant effects, was reported (Fell et al., 2011) . Although preclinical data hold promise for mGlu2 PAMs as novel therapeutics, clinical proof of concept is awaited with more drug-like compounds compared with the first-generation PAMs.
Here, we describe the in vitro and in vivo properties of the novel PAM 3-cyano-1-cyclopropylmethyl-4-(4-phenyl-piperidin-1-yl)-pyridine-2(1H)-one (JNJ-40068782) (Imogai et al., 2007; Cid et al., 2008) . We furthermore describe [
3 H]JNJ-40068782 as the first high-affinity, selective mGlu2 PAM radioligand and show that this is an excellent tool to study allosteric mGlu2 interactions. HEPES, EGTA, bovine serum albumin (BSA), probenecid, and glutamate were purchased from Sigma-Aldrich (St. Louis, MO); MgCl 2 was purchased from VWR Prolabo (Belgium), saponin was from Calbiochem(San Diego, CA), Hanks' balanced salt solution (HBSS) and fluo-4-AM were from Invitrogen (Carlsbad, CA), and phenylmethanesulfonyl fluoride from Fluka (Buchs, Switzerland). All other reagents were obtained from Merck (Darmstadt, Germany). For in vitro experiments, concentration-response curves of JNJ-40068782 were prepared in 100% dimethylsulfoxide and further diluted in assay buffer with final assay concentrations reaching 1% dimethylsulfoxide. For in vivo studies, JNJ-40068782 solutions were prepared in 20% hydroxypropyl-b-cyclodextrine.
Materials and Methods
BINA, LY487379, THIIC (LY2607540), 1-butyl-4-[4-(2-methylpyridin- 4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-
Tritiation of JNJ-40068782
The brominated precursor 4-(4-(4-bromophenyl)piperidin-1-yl)-1-(cyclopropylmethyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile was dissolved in tetrahydrofuran. N,N-Diisopropylethylamine and palladium 10% on carbon then were added. The reaction mixture was attached to a tritium manifold (RC Tritec, Teufen, Switzerland), and 183 megabars of tritium gas was placed on top of the reaction mixture and was stirred for 1 hour at room temperature. The remaining tritium gas was trapped on a uranium bed, and all volatile compounds were lyophilized to a waste ampoule. The crude reaction mixture was rinsed with methanol, dissolved in ethanol, and filtered over an Acrodisc filter, yielding 16.4 GBq. A small portion of this material was further purified and analyzed by high-performance liquid chromatography to obtain the tritiated compound 4-(4-(4-tritiumphenyl)piperidin-1-yl)-1(cyclopropylmethyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (radiochemical purity of .98%; 865 GBq/mmol).
Functional mGlu2 Assays
Ca 21 Assay. Intracellular Ca 21 levels were measured using the Functional Drug Screening System (FDSS 6000; Hamamatsu Photonics, Hamamatsu City, Japan). Human mGlu2 receptor-expressing Ga 16 -HEK293 cells were seeded at 10,000 cells/well in 384-well black/ clear-bottom poly-D-lysine-coated plates 24 hours before the experiment. On the day of the experiment, medium was removed by brief centrifugation, and 20 ml of a fluo-4-AM solution (HBSS buffer containing 20 mM HEPES, 2.5 mM probenecid, and ∼2 mM fluo-4-AM, pH 7.4) was added. After an incubation period of 1 hour at room temperature in the dark, 40 ml buffer was added, and cells were kept at room temperature for another 10 minutes before measurement. Fluorescence was recorded upon the addition of compound (20 ml), and the ratio of the peak over basal fluorescence was exported and used for further calculation. For the measurement of intrinsic agonism, compound was added alone (i.e., in the absence of glutamate); for measurement of PAM activity, compound was added together with an EC 20 -equivalent concentration of glutamate (0.3 mM).
[ 35 S]GTPgS Binding. Chinese hamster ovary (CHO) cells expressing the rat or human mGlu2 receptor were grown until 80% confluence, washed in ice-cold phosphate-buffered saline, and stored at 220°C until membrane preparation. After thawing, cells were suspended in 50 mM Tris-HCl, pH 7.4, and collected through centrifugation for 10 minutes at 23,500g at 4°C. Cells were lysed in 5 mM hypotonic Tris-HCl, pH 7.4; and after recentrifugation for 20 minutes at 30,000g at 4°C, the pellet was homogenized with an Ultra Turrax homogenizer (IKA-Werke GmbH & Co. KG, Staufen, Germany) in 50 mM Tris-HCl, pH 7.4. Protein concentrations were measured by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA) using BSA as standard.
For [
35 S]GTPgS measurements, compound and glutamate were diluted in buffer containing 10 mM HEPES acid, 10 mM HEPES salt, pH 7.4, containing 100 mM NaCl, 3 mM MgCl 2 , and 10 mM GDP. Membranes were thawed on ice and diluted in the same buffer, supplemented with 14 mg/ml saponin (final assay concentration of 2 mg/ml saponin). Final assay mixtures contained 7 (human mGlu2) or 10 mg (rat mGlu2) of membrane protein and were preincubated with compound alone (determination of agonist effects) or together with an EC 20 concentration (4 mM) of glutamate (Happe et al., 2001 ). Hence, 20-mmthick sagittal sections were incubated twice in assay buffer, pH 7.5 (50 mM Tris-HCl, 10 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, 0,1 mM phenylmethanesulfonyl fluoride, and 1% BSA), for 10 minutes at 25°C and once in assay buffer with 2 mM GDP for 15 minutes at 25°C. Slides were then incubated in assay buffer containing 0.04 nM [ 35 S]GTPgS in the presence or absence of 10 mM glutamate and increasing concentrations of JNJ-40068782 for 2 hours at 25°C. The incubation was stopped by washing twice for 3 minutes in ice-cold 50 mM Tris-HCl, pH 7.4, and a quick dip in ice-cold distilled water.
Sections were then dried under a cold stream of air and placed in a light-tight cassette together with commercially available radioactive polymer standards and exposed to Kodak Biomax MR film (PerkinElmer Life and Analytical Sciences) for 4 days. Films were developed by standard techniques, digitized, and analyzed using the MCID basic 7.0 system (Imaging Research, St. Catharines, ON, Canada).
Agonist-stimulated activity in brain sections was calculated by subtracting the optical density in basal sections (incubated with GDP alone) from that of agonist-stimulated sections; results were expressed as percentage basal activity.
Radioligand Binding to Human mGlu2-CHO Membranes or Rat Cortical Membranes
Membranes from human mGlu2 receptor stably transfected CHO cells were prepared as above (see "[
35 S]GTPgS Binding" under Materials and Methods). For cortical membranes, male Wistar rats (150 g) were sacrificed and decapitated. Brains were removed, and cortex tissue was dissected and kept on ice. Tissue was homogenized with an Ultra-Turrax homogenizer in 50 mM Tris-HCl, pH 7.4; and the homogenate was centrifuged for 10 minutes at 16,000 rpm. The pellet was resuspended and homogenized again with a glass Teflon homogenizer (Dual; Thomas Scientific, Swedesboro, NJ). After two washing/centrifugation steps, the final pellet was resuspended in 50 mM Tris-HCl, pH 7.4. Aliquots were made and frozen at 280°C until further use. Protein concentration was determined with the BioRad Protein Assay method using BSA as standard.
After thawing, membranes were homogenized using an Ultra Turrax homogenizer and suspended in ice-cold binding buffer containing 50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , and 2 mM CaCl 2 .
[ 3 H]LY341495 Binding. For competition binding studies, assay mixtures were incubated for 60 minutes at room temperature in a volume of 0.5 ml containing 10-mg membrane protein (hmGlu2 CHO), appropriate concentrations of test compound, and 2 nM [ 3 H]LY341495. Nonspecific binding was determined in the presence of 1000 mM glutamate and was approximately 10% of total binding. The incubation was stopped by rapid filtration using Unifilter-96 GF/B filter plates and a Unifilter-96 harvester.
[ were tested). Nonspecific binding (~30% of total binding) was determined in the presence of 10 mM LY341495. H]JNJ-40068782 were incubated for 60 minutes at room temperature in a total volume of 0.5 ml. Nonspecific binding (~30% of total binding) was determined in the presence of 10 mM JNJ-40264796, a structurally related molecule. Displacement studies were performed using 10 nM radioligand. Filtration was performed using Unifilter-96 GF/C filters presoaked in 0.1% polyethylenimine and a 40-well manifold or 96-well Brandel harvester 96 (Brandel, Inc., Gaithersburg, MD).
For (200 g) were sacrificed by decapitation. Brains were immediately removed from the skull and then rapidly frozen in dry ice-cooled 2-methylbutane (240°C). Brains were then stored at 220°C until sectioning. Sagittal sections (20 mm) were cut using a Leica C3050 cryostat microtome (Leica Microsystems, Wetzlar, Germany) and thaw-mounted on SuperFrost Plus microscope slides (Menzel-Glaser GmbH, Braunschweig, Germany). The sections were then kept at 220°C until use. Male wild-type C57BL/6 and mGlu2 knockout mice (Deltagen, Inc., San Mateo, CA) weighing 25-30 g were killed by decapitation, and their brains were prepared as stated above.
Receptor Autoradiography. Sections were thawed and dried under a stream of cold air and preincubated (2 Â 10 minutes) at room temperature in incubation buffer (50 mM Tris-HCl, 2 mM MgCl 2 , and 2 mM CaCl 2 , pH 7.4). Sections were then incubated for 60 minutes at room temperature in buffer containing 10 nM [ 3 H]JNJ-40068782 with nonspecific binding determined by addition of 10 mM JNJ-40068782. After incubation, the excess of radioligand was washed off (2 Â 10 minutes) in ice-cold buffer, followed by a rapid dip in cold distilled water. The sections were dried under a stream of cold air. Rat brain sections were exposed to [ 3 H]Hyperfilm (Amersham Biosciences, Buckinghamshire, UK) for 6 weeks at room temperature. The films were developed manually in Kodak D19 and fixed with Kodak Readymatic (Eastman Kodak, Rochester, NY). Mouse brain sections were exposed for 6 days to a PhosphorImager screen. Digital autoradiograms were obtained using a PhosphorImager FLA7000 (Fuji, Tokyo, Japan).
Selectivity Panel
Ca 21 Assays with Human mGlu1, -3, -5, -7, or -8 Receptor-Expressing HEK293 Cells. Measurement of intracellular Ca 21 mobilization in HEK293 cells stably transfected with the human mGlu1a receptor proceeded as follows. Cells were seeded at 10,000 cells/well in a 384-well plate. Twenty-four hours after seeding, FLIPR Ca 21 assay kit (Molecular Devices, Sunnyvale, CA) dissolved in phosphate-buffered saline supplemented with 5 mM probenecid, pH 7.4 (c.f. 2.5 mM probenecid, as loading buffer was added on the cell layer with no removal of medium) was added, and measurements were initiated 90 minutes thereafter.
Ca 21 assays with human mGlu3 receptor-expressing Ga 16 -HEK293 cells were performed similarly as for human mGlu2-expressing cells, with the following exception: cells were seeded at a density of 10,000 cells/well, and cell incubation with fluo-4-AM took place at 37°C instead of room temperature.
For the mGlu5 receptor, cells were seeded at 40,000 cells/well in poly-D-lysine-coated 384-well plates, and a day later, medium was removed before addition of a fluo-4-AM solution (HBSS, 2.5 mM probenecid, and ∼2 mM fluo-4-AM; pH 7.4). Before measurement, cells were incubated for 90 minutes at 37°C and 5% CO 2 .
For the human mGlu7 and -8 receptor, stably expressing Ga 15 -HEK cells were seeded at a density of 15,000 cells/well (poly-D-lysinecoated 384-well plates) and incubated with FLIPR Calcium 4 assay kit (dissolved in HBSS, 20 mM HEPES, and 2.5 mM probenecid, pH 7.4) for 90 minutes at 25°C before measurement.
The ratio of peak versus basal fluorescent signals was used for data analysis.
[ 35 S]GTPgS Binding to Membranes from CHO Cells Expressing the Rat mGlu6 Receptor and to Membranes from L929sA Cells Expressing the Human mGlu4 Receptor. Membrane preparations were performed as described above (see "[
S]GTPgS
Binding" under Materials and Methods). Membranes, compound, and glutamate were diluted in assay buffer (10 mM HEPES acid, 10 mM HEPES salt, pH 7.4, containing 100 mM NaCl, 0.3 mM MgCl 2 , and 10 mM GDP). Assay mixtures included 10 mg of membrane protein and were preincubated with compound alone or together with glutamate for 30 minutes at 37°C. [ Selectivity of JNJ-40068782 in Additional Radioligand Binding Assays. JNJ-40068782 was tested at a concentration of 10 mM by CEREP (Celle L'Evescault, France) for its inhibition of radioligand binding to a battery of neurotransmitter and peptide receptors, ion channels, and transporters.
Data Analysis. For both [ 35 S]GTPgS and Ca 21 mobilization assays, data were processed using either the Lexis software interface developed at Janssen Research and Development or GraphPad Prism version 4.02 (GraphPad Software, Inc., La Jolla, CA) and were calculated as percentage of the control agonist challenge. Sigmoid concentrationresponse curves plotting percentages of effect versus the log concentration of the test molecule were analyzed using nonlinear regression analysis.
To further describe the signaling of glutamate in the presence of a PAM, the fold shift of the glutamate concentration-response was plotted as a function of the concentration of modulator in GraphPad Prism version 4.02 using nonlinear regression; interpolation was then used to allow estimates of concentrations needed for a 5-fold shift.
Inhibition [ 3 H]JNJ-40068782 binding data were fitted to a one-site binding model (GraphPad Prism version 4.02) and estimates of dissociation constants (K i ) were derived using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . Saturation binding experiments were analyzed using nonlinear regression (one-site binding hyperbola; GraphPad Prism version 4.02).
In Vivo Studies
All animal experiments were carried out in strict accordance with the Declaration of Helsinki and the European Communities Council Directive of 24th November 1986 (86/609/EEC) and were approved by the Animal Ccare and Use Committee of Janssen Research and Development as well as the local ethical committee.
Pharmacokinetic Analysis. Animals were given free access to food and water overnight before dosing and throughout the study. Male Sprague-Dawley rats were given a single oral dose of 10 mg/kg. Blood samples were taken at 0.5, 1, 2, 4, 8, and 24 hours from the tail vein using EDTA as the anticoagulant. Male Swiss mice were dosed with a dose of 10 mg/kg s.c., and blood samples were taken at 0.5, 1, and 1.5 hours after dosing. Plasma was obtained following centrifugation, extracted using protein precipitation, and subsequently analyzed for JNJ-40068782 using a liquid chromatography/tandem Pharmacological Characterization of JNJ-40068782, an mGlu2 Receptor PAM mass spectrometry qualified research method on an API4000 instrument (Applied Biosystems, Foster City, CA).
Sleep-Wake Architecture Study in Rat. Male Sprague-Dawley rats (Charles River Laboratories, Les Oncins, France) weighing 250-300 g at the time of surgery were used. The effect of oral administration of JNJ-40068782 (administered orally 2 hours after light onset using a dose volume of 10 ml/kg) on sleep-wake organization in rats was determined as described in Ahnaou et al. (2009) . In brief, sleep polysomnographic variables were determined in 32 adult, male Sprague-Dawley rats (n 5 8 in each group), which were chronically implanted with electrodes for recording the cortical electroencephalogram (EEG), electrical neck muscle activity, and ocular movements. Polysomnographic data were scored with an automated sleep stages analyzer, scoring each 2-second epoch before averaging stages over 30-minute periods. Sleep-wake state classifications were assigned based upon the combination of dynamics of five EEG frequency domains, integrated electrical neck muscle activity (EMG), ocular movements (EOG), and body activity level as follows: active wake; passive wake; rapid eye movement (REM) sleep; intermediate stage (pre-REM transients); light non-REM sleep; and deep non-REM sleep. Different sleep-wake parameters such as amount of time spent in each state were investigated over 20 postadministration hours.
Time spent in each sleep-wake state was expressed as a percentage of the recording period. A statistical analysis of the obtained data was carried out by a nonparametric analysis of variance of each 30-minute period, followed by a Wilcoxon-Mann-Whitney rank sum test of comparisons with the control group.
Phencyclidine-Induced Hyperlocomotion in Mice. Test compound or solvent was administered alone (to monitor effects on spontaneous locomotion) or together with phencyclidine (PCP; 5 mg/kg) to male NMRI mice (22 6 4 g and fasted overnight; Charles River Laboratories) 30 minutes before measurement. Both JNJ-40068782 and PCP were injected subcutaneously, and locomotor activity was measured for a period of 30 minutes. ED 50 values (the doses inducing 50% responders to criterion) were determined as follows.
All-or-nothing criteria for significant (P , 0.05) effects were defined by analyzing a frequency distribution of a large series of historical control data obtained in solvent-treated animals. Based on the criteria obtained in this way, the ED 50 and corresponding 95% confidence limits were determined according to the modified Spearman-Kaerber estimate, using theoretical probabilities instead of empirical ones. This modification allows determination of the ED 50 and its confidence interval (CI) as a function of the slope of the log dose-response curve. The criterion for druginduced decrease of spontaneous locomotion was total distance of ,2500 counts (4.1% false positives in controls; n 5 410). The criterion for drug-induced inhibition of PCP-induced hyperlocomotion was total distance of ,5500 counts (3.9% false positives in controls; n 5 154).
Results

JNJ-40068782
Acts as a Selective PAM at the mGlu2 Receptor. Figure 2 shows the concentration-response curves for the glutamate-stimulated increase in [
35 S]GTPgS binding in absence and presence of JNJ-40068782, BINA, LY487379, or LY2607540. JNJ-40068782, similar to the other PAMs, enhances the glutamate-stimulated increase in [
35 S]GTPgS. It is noteworthy that all compounds magnified the response produced by glutamate, shifting the glutamate concentrationeffect curve both upward and leftward. Whereas a concentration of 429 nM BINA, 568 nM JNJ-40068782, or 305 nM LY2607540 increases the glutamate potency (i.e., lowers the glutamate EC 50 ) 5-fold, LY487379 causes only a 2-to 3-fold shift in the glutamate concentration-response curve at the highest tested concentration of 1 mM. Maximal decreases in glutamate EC 50 of 10-to 12-fold are observed for the other compounds.
By quantifying the increase in response at a fixed glutamate concentration, for example, the glutamate EC 20 , the potency (EC 50 ) of JNJ-40068782 at the human mGlu2 receptor was estimated to be 143 nM ( Fig. 2B ; Table 1 ). This value is similar (overlapping CIs) to the potencies of BINA, LY487379, and LY2607540 (respective EC 50 values of 89, 256, and 95 nM). The maximal response to glutamate was increased to 309 6 23% upon addition of JNJ-40068782, which is similar to the potentiation seen with BINA and LY2607540 (221 6 9 and 215 6 7%, respectively) (Table 1) . However, LY487379 showed a more modest, 147 6 9% increase in glutamate E max . Although both EC 50 and E max values slightly increased at the rat compared with the human mGlu2 receptor, we found a good similarity between compound potencies obtained in the rat and human assays (Table 1) .
At higher concentrations, JNJ-40068782 also increased [ 35 S]GTPgS binding in the absence of glutamate, suggesting that it acts as an "ago-potentiator." Similar profiles were observed for BINA and LY2607540 but not LY487379. It is noteworthy that JNJ-40068782 along with the reference compounds acted as a pure mGlu2 receptor PAM at recombinant rat mGlu2 receptors (i.e., did not have any intrinsic activity in the absence of glutamate) ( Table 1) .
Further profiling of JNJ-40068782 showed that it also facilitated glutamate-induced Ca 21 mobilization at human recombinant mGlu2 receptors. In HEK293 cells coexpressing Ga 16 , JNJ-40068782 potentiated the EC 20 glutamate response with an EC 50 value of 15 nM (95% CI, 12-19 nM; n 5 30). It is noteworthy that, in this assay, JNJ-40068782 did not increase the maximal response of glutamate (E max 5 119 6 2%; also see Fig. 2C ). JNJ-40068782 induced intracellular Ca 21 mobilization on its own (allosteric agonism) with an EC 50 of 618 nM (95% CI 497-768 nM) and E max of 81 6 3% (n 5 25). JNJ-40068782 did not show agonist, antagonist, or PAM activity at the human mGlu3 receptor or any of the group I or group III mGlu receptors up to 10 mM (data not shown (Fig. 3) . Although this may imply that JNJ-40068782 has intrinsic direct agonist effects at native rat mGlu2 receptors (i.e., can activate mGlu2 receptors in the absence of glutamate), the possibility that this may be a modulation of endogenous glutamate that was not removed during washing of the slices cannot be excluded. In the presence of 10 mM glutamate, JNJ-40068782 produced a robust increase in [ 35 S]GTPgS binding, particularly in the cortex, striatum, and hippocampus (Fig. 3) . Potentiation of glutamate by JNJ-40068782 was evident at the lowest concentration of the allosteric modulator, and quantification of these data showed that although 10 mM glutamate or 1 mM JNJ-40068782 alone increased [
35 S]GTPgS binding in the cortex by ∼10 and ∼20%, respectively, the combination led to a stimulation of ∼80%. In combination with glutamate, a maximal stimulation of ∼175% was detected after the addition of 10 or 100 mM JNJ-40068782; in the absence of glutamate, 100 mM JNJ-40068782 increased the response to 125%. Hence, although the potency of JNJ-40068782 on [ 35 S]GTPgS binding at native rat receptors is reduced relative to recombinant systems, presumably as a result of the complication of endogenous glutamate, the anatomic distribution of the responses (i.e., preferential stimulation of the binding in the cortex, striatum, and hippocampus) is consistent with an mGlu2 receptor-mediated response.
JNJ 3 H]LY341495 binding to the human mGlu2 receptor was not inhibited upon the addition of 10 mM JNJ-40068782 (Fig. 4A) . In contrast to the lack of effect of JNJ-40068782 on the binding of the antagonist radioligand, binding of the radiolabeled orthosteric agonist [ 3 H]DCG-IV was increased up to 2.5-fold upon the addition of JNJ-40068782 at 3 mM (Fig. 4B) . In line with previous data, JNJ-40068782 not only increased the maximal binding but also enhanced the affinity of glutamate, i.e., lowered the IC 50 of glutamate by ∼5-fold (4.5-and 6.7-fold found in two independent experiments) (Fig. 5B ).
Binding of [ 3 H]JNJ-40068782 to Recombinant Human mGlu2 Receptors. JNJ-40068782 was tritiated and used to characterize the binding to human recombinant mGlu2 receptors (Fig. 6A) . Binding was saturable and was best-fit to a single-site model defined by a K D of 12 6 4 nM with a B max of 4.5 6 1.9 pmol/mg protein (n 5 12). At a concentration of 10 nM, the level of specific binding was in the region of 70%. It is noteworthy that, in the presence of agonist (either glutamate, DCG-IV, or LY354740), the apparent affinity of [ 3 H]JNJ-40068782 was increased (average K D in the presence of 100 mM glutamate was 4.0 6 1.2 nM; n 5 4), with the saturation curve being leftward-shifted (Fig.  6B) 3 H]JNJ-40068782 bound with a similar affinity to receptors expressed in rat cortex; K D and B max were 10 6 4 nM (c.f. 12 6 4 nM at human recombinant mGlu2 receptors) and 14.7 6 5.7 pmol/mg protein (n 5 6), respectively. IC 50 values for displacing cortical mGlu2 receptors were 52 nM (95% CI 34-78 nM; n 5 7), 617 nM (95% CI 242-1571 nM; n 5 5), 102 nM (95% CI 55-190 nM; n 5 5), and 79 nM (95% CI 43-143 nM; n 5 3) for JNJ-40068782, BINA, LY483739, and LY2607540, respectively (assuming a competitive interaction, K i values are 26, 305, 51, and 39 nM, respectively), confirming that these PAMs also bind to native receptors (Fig. 7B) .
By use of radioligand autoradiography, we examined [ 3 H]JNJ-40068782 binding distributions in rat brain sections in further detail (Fig. 8A) . High specific binding was observed in the hippocampal formation, granular layer of the cerebellum, striatum, and cortex, corresponding very well with the expression pattern demonstrated using the mGlu2/3 receptor antagonist [
3 H]LY341495. [ 3 H]JNJ-40068782 binding site distribution was similar in wild-type mouse brain. It is important to note that binding was lost in mGlu2 knockout mice, underlining the mGlu2 specificity of the radioligand (Fig. 8B) .
Effects of JNJ-40068782 on Sleep-Wake Organization in the Rat. The preceding data collectively demonstrate that JNJ-40068782 not only binds to native mGlu2 receptors but Pharmacological Characterization of JNJ-40068782, an mGlu2 Receptor PAM also selectively potentiates the functional response at rat brain mGlu2 receptors. As JNJ-40068782 was shown to be brain-penetrant (with C max of ∼1400 ng/ml and brain-toplasma ratio of ∼0.4 after oral dosing of 10 mg/kg in rats), we set out to evaluate some of the in vivo functional effects of this novel mGlu2 receptor PAM.
We have previously shown that selective activation or positive allosteric modulation of the mGlu2 receptor in vivo affects the sleep-wake architecture of rats (Ahnaou et al., 2009 ). To assess whether JNJ-40068782 has in vivo central activity, we evaluated sleep-wake organization of rats after oral dosing of JNJ-40068782.
The time course of vigilance states over 20 hours following administration of vehicle and JNJ-40068782 is illustrated in Fig. 9 . Acute administration of JNJ-40068782 (3, 10, and 30 mg/kg PO) significantly suppressed the time spent in REM sleep and intermediate stage, whereas no major effects on the other sleep-wake stages were observed. Quantification of effect over a 4-hour time period following compound administration revealed a dose-related reduction in time spent in REM sleep with a lowest active dose of 3 mg/kg PO, corresponding to a plasma drug concentration of ∼420 ng/ml. REM sleep reduction was accompanied by consistent lengthening in REM sleep onset latency (Fig. 9 , upper small bar graph panel in REM sleep stage).
Effects of JNJ-40068782 on PCP-Induced Hyperactivity in Mice. The effects of JNJ-40068782 on spontaneous locomotor activity was measured at doses ranging from 2.5 to 10 mg/kg s.c. (Fig. 10A) . The compound produced a modest reduction in spontaneous activity, with the total distance traveled dropping by 20% from 2974 cm in vehicle-treated mice to 2365 cm in animals receiving 20 mg/kg JNJ-40068782.
We subsequently evaluated whether JNJ-40068782 was able to mimic some of the effects of mGlu2/3 agonists in an animal model that is used to predict potential antipsychotic activity. At a dose of 5 mg/kg s.c., PCP induces a profound increase in the total distance traveled by mice. Subcutaneous injection of JNJ-40068782 significantly attenuated the increase in locomotor activity evoked by PCP, with an ED 50 of 5.7 mg/kg s.c., corresponding to a plasma drug concentration of ∼1700 ng/ml (Fig. 10B ).
Discussion
The pioneering work emanating from Eli Lilly using mGlu2/3 orthosteric (glutamate) binding site agonists such as LY404039 and LY354740 has defined the group II mGlu receptor subfamily as an attractive potential therapeutic target for anxiety disorders and schizophrenia (Swanson et al., 2005; Fell et al., 2012) . A key role of the mGlu2 receptor in mediating the pharmacological effects observed with mGlu2/3 receptor agonists is emphasized by data demonstrating that compounds that selectively potentiate the effects of glutamate at mGlu2 receptors (mGlu2 PAMs) can reproduce some of the effects seen with the nonselective mGlu2/3 receptor agonists. Such compounds include N- (49-cyano-[1,19-biphenyl]-3-yl-N-(3-pyridinylmethyl) ethanesulfonamide , BINA (Galici et al., 2005 (Galici et al., , 2006 , and LY487379 (Johnson et al., 2003; Schaffhauser et al., 2003; Galici et al., 2005) .
Our studies have provided new pharmacological tools to study the mGlu2 receptor PAM concept, including JNJ-40068782 and [ 3 H]JNJ-40068782. Although the in vitro potencies for the reference mGlu2 receptor PAMs vary from laboratory to laboratory, presumably as a result of differences in receptor expression systems and/or assay methodologies, it nevertheless seems that LY487379 is consistently less potent (with in vitro potency for the human mGlu2 receptor ranging from ∼250 nM to ∼1.5 mM) than BINA, LY2607540, and JNJ-40068782, all of which may be considered equipotent (with potencies ranging from ∼20 nM to 1 mM depending on the assay).
By use of a [ 35 S]GTPgS assay for mGlu2 receptors expressed in CHO cells, there does not seem to be any marked rat versus human species differences for the four abovementioned PAMs, although EC 50 values were generally 2-fold lower, and E max was 1.5-fold higher between rat and human mGlu2 data. Screening of .100 additional compounds furthermore confirmed this pattern, with no examples of compounds being active in one species but not the other (data not shown; correlation plots can be found in Supplemental  Fig. 1 ). JNJ-40068782 induced a receptor response even in the absence of agonist in some but not all in vitro assays, indicating that the functional effects of this molecule can be different depending on the functional readout as well as the level of receptor expression and hence seem contextdependent. This is in line with the thinking that ligand "behaviors" rather than inherent "properties" can be described and that detection of agonist "behavior" depends on the ligand and sensitivity of the assay used (Langmead, 2012) . It also cannot be ruled out that the response can, at least in part, be attributed to the presence of endogenous glutamate.
It Allosteric modulators may enhance the efficacy of the endogenous agonist not only by "magnifying" the intracellular responses produced by the agonist but also by altering the apparent affinity of the agonist, or a mixture of the two (Conn et al., 2009 [Cosford et al., 2003] ) receptors. Recently, a novel mGlu2/3 receptor agonist radioligand was reported (Wright et al., 2013 ). However, [ 3 H]JNJ-40068782 is the first selective mGlu2 radioligand that is described extensively. JNJ-40068782 was selective for mGlu2 receptors as defined by CEREP profiling, where only a significant interaction at CCK A receptors, which are known to be expressed only in very discrete brain regions such as the interpeduncular nucleus and nucleus tractus solitarius (Hill et al., 1987) , was observed at 10 mM JNJ-40068782. At relatively high concentrations, JNJ-40068782 also acted on the 5HT 2A receptor (IC 50 , ∼10 mM); it is, however, unlikely that it reaches sufficient amounts in vivo to trigger a functional 5HT 2A -related effect. Using [ we did not observe in vivo binding up to 30 mg/kg PO (data not shown); also in addition, JNJ-40068782 did not affect sleepwake behavior in rats, whereas ample evidence exists for modulation of deep non-REM sleep via the 5HT 2A receptor (Al-Shamma et al., 2010 3 H]DCG-IV is interesting and may suggest that PAMs preferentially bind to certain receptor states that are not necessarily similar to those preferentially recognized by DCG-IV. Alternatively, JNJ-40068782 may bind to only one of the subunits within the mGlu2 homodimer, whereas DCG-IV likely binds to both, which might be consistent with previous reports that binding and closure of both extracellular domains within the mGlu receptor dimer are needed for full activity, whereas only a single heptahelical domain is turned on upon receptor activation (Kniazeff et al., 2004; Hlavackova et al., 2005) . Even more intriguing is the finding that, in the presence of agonists (glutamate or LY354740), the B max of [ 3 H]JNJ-40068782 was consistently increased, opening the possibility of a changed receptor conformation allowing binding to both receptor subunits in the mGlu2 receptor dimer, upon which a "superactivated" state may be imposed.
Because of its specificity, [
3 H]JNJ-40068782 proved to be suitable for investigation of mGlu2 receptor distribution in brain sections using radioligand autoradiography. These studies showed that the highest level of mGlu2-specific binding was present in the hippocampus, striatum, cortex, and granular layer of the cerebellum. These results correspond to the binding of [ (Ohishi et al., 1993 (Ohishi et al., , 1998 Gu et al., 2008) .
JNJ-40068782 proved to have appropriate pharmacological and pharmacokinetic properties to evaluate its effects in vivo. It is well established that mGlu2 receptor modulation affects sleep-wake architecture in rats and mice (Feinberg et al., Ahnaou et al., 2009; Fell et al., 2011) . Consistent with these data, we found that JNJ-40068782 dose-dependently decreased the amount of REM sleep in rats when dosed early in the light phase. The effects on sleep-wake organization in rats may well reflect the modulation of physiologic glutamatergic signaling because it has been shown that glutamate levels are increased during REM sleep in rat orbitofrontal and cerebral cortex (Lopez-Rodriguez et al., 2007; Dash et al., 2009) . Moreover, because of the translational nature of the sleep-wake EEG paradigm, polysomnography measurements in man may be used as a reproducible and sensitive biomarker. Nevertheless, it remains to be determined to what extent the changes in REM sleep, although a reliable pharmacodynamic marker, have relevance for potential mGlu2-mediated therapeutic efficacy.
As regards potential therapeutic indications for mGlu2 receptor modulation, JNJ-40068782 decreased PCP-induced hyperlocomotion, which is a model in which dopamine D 2 -related antipsychotics demonstrate robust efficacy. However, the doses at which JNJ-40068782 is active in this model correspond to plasma drug concentrations somewhat higher than those in the sleep-wake organization paradigm, although this may merely reflect the fact that greater drug concentrations may be required to demonstrate efficacy in a challenge model (PCP-induced hyperactivity) compared with a more physiologic situation (sleep-wake). Although these findings provide more evidence that mGlu2 PAMs can mimic aspects of the pharmacology of mGlu2/3 receptor agonists, and hence have the potential to exhibit antipsychotic behavior, studies are ongoing to provide more insight into the translation of compound activities in preclinical animal models into relevant dose levels in a clinical setting.
Collectively, our data indicate that JNJ-40068782 is a selective PAM of native and recombinant rat and recombinant human mGlu2 receptors. It not only enhances the affinity of agonists but also increases the maximal response. In the absence of exogenous glutamate, JNJ-40068782 has a modest degree of intrinsic agonist efficacy. [ 3 H]JNJ-40068782 represents an excellent novel radiotracer to study mGlu2 allosteric interaction, expression, and distribution. With [ 3 H]JNJ-40068782, we show for the first time that agonists also influence the affinity of PAMs. Finally, since JNJ-40068782 is active in vivo, it is a suitable pharmacological tool to increase our understanding of how mGlu2 receptor modulation may affect diseases in which glutamatergic transmission is disrupted.
